Implantation of a three-dimensional fibroblast matrix improves left ventricular function and blood flow after acute myocardial infarction.
This study was designed to determine if a viable biodegradable three-dimensional fibroblast construct (3DFC) patch implanted on the left ventricle after myocardial infarction (MI) improves left ventricular (LV) function and blood flow. We ligated the left coronary artery of adult male Sprague-Dawley rats and implanted the 3DFC at the time of the infarct. Three weeks after MI, the 3DFC improved LV systolic function by increasing (p < 0.05) ejection fraction (37 +/- 3% to 62 +/- 5%), increasing regional systolic displacement of the infarcted wall (0.04 +/- 0.02 to 0.11 +/- 0.03 cm), and shifting the passive LV diastolic pressure volume relationship toward the pressure axis. The 3FDC improved LV remodeling by decreasing (p < 0.05) LV end-systolic and end-diastolic diameters with no change in LV systolic pressure. The 3DFC did not change LV end-diastolic pressure (LV EDP; 25 +/- 2 vs. 23 +/- 2 mmHg) but the addition of captopril (2mg/L drinking water) lowered (p < 0.05) LV EDP to 12.9 +/- 2.5 mmHg and shifted the pressure-volume relationship toward the pressure axis and decreased (p < 0.05) the LV operating end-diastolic volume from 0.49 +/- 0.02 to 0.34 +/- 0.03 ml. The 3DFC increased myocardial blood flow to the infarcted anterior wall after MI over threefold (p < 0.05). This biodegradable 3DFC patch improves LV function and myocardial blood flow 3 weeks after MI. This is a potentially new approach to cell-based therapy for heart failure after MI.
Thai
Hoang M
HM
Section of Cardiology, Department of Medicine and Pathology, Southern Arizona VA Health Care System, Sarver Heart Center, University of Arizona, Tucson, AZ, USA.
Juneman
Elizabeth
E
Lancaster
Jordan
J
Hagerty
Tracy
T
Do
Rose
R
Castellano
Lisa
L
Kellar
Robert
R
Williams
Stuart
S
Sethi
Gulshan
G
Schmelz
Monika
M
Gaballa
Mohamed
M
Goldman
Steven
S
D000208:Acute Disease; D000818:Animals; D001794:Blood Pressure / Q000187:drug effects; D002216:Captopril / Q000494:pharmacology; D003326:Coronary Circulation / Q000187:drug effects / Q000502:physiology*; D004452:Echocardiography; D005109:Extracellular Matrix / Q000187:drug effects / Q000637:transplantation*; D005169:Factor VIII / Q000378:metabolism; D005347:Fibroblasts / Q000187:drug effects / Q000637:transplantation* / Q000648:ultrastructure; D006439:Hemodynamics / Q000187:drug effects; D009203:Myocardial Infarction / Q000503:physiopathology*; D019919:Prosthesis Implantation; D051381:Rats; D012039:Regional Blood Flow / Q000187:drug effects; D013599:Systole / Q000187:drug effects; D016277:Ventricular Function, Left / Q000187:drug effects / Q000502:physiology*
D005169:Factor VIII; D002216:Captopril